The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study
司天梅,舒良,吉中孚,李惠春,陶明,唐永怡,李晓光,季建林,史以玉,王崇顺,梅其一,欧红霞,翁正,王铭,端义扬,秦晓霞,金雪光
DOI: https://doi.org/10.3760/j:issn:1006-7884.2006.02.006
2006-01-01
Abstract:Objective The aim of this naturalistic open-label study was to contribute further information on the long-term efficacy and tolerability of venlafaxine extended releasing form in Chinese patients with major depression.Methods A multi-center,open-label study was specifically designed to prospectively understand the efficacy and safety of flexible dose of venlafaxine in treating major depression for 16 weeks.All patients met the ICD-10 criteria for depressive disorders and were assessed with the Hamilton Depression Rating Scale(HAMD),Hamilton Anxiety Rating Scale(HAMA),Clinical Global Impression(CGI) and side effects,including the lab test and blood pressure,at baseline and on weeks 2,4,8 12 and 16.Results Altogether 350 patients were enrolled in the study,with 144 males and the mean age of 37 years old.In 321 patients who completed 16 week treatment,significant reductions in HAMD and HAMA,and subscale of HAMD scores were seen from baseline on week 2 and continuing to week 16,and 67.3% of patients were clinical remission(total score of HAMD ≤7).The dosage in patients with recurrent episodes was higher than that with first episode,and the efficacy in acute patients was better than in chronic patients.The common side effects were temporal dizziness,vomit and hyperhidrosis.There were not significant changes for the blood pressure after treatment.Conclusion The extended releasing venlafaxine is an efficient antidepressant with better tolerability,it is suitable for long-term preventive treatment.